Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (PIONEER 4)
Sponsor: Novo Nordisk A/S
This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 2 and is currently completed. Novo Nordisk A/S leads this study, which shows 19 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 14 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2020 — Apr 2020 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Completed PHASE3
-
Jul 2019 — Dec 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Jul 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
May 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .